International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Danne, Thomas; K. Garg, Satish; L. Peters, Anne; B. Buse, John; Mathieu, Chantal; Pettus, Jeremy; M. Alexander, Charles; Battelino, Tadej; Javier Ampudia‐Blasco, Francisco; W. Bode, Bruce; Cariou, Bertrand; L. Close, Kelly; Dandona, Paresh; Dutta, Sanjoy; Ferrannini, Ele; Fourlanos, Spiros; Grunberger, George; Heller, Simon; R. Henry, Robert; J. Kurian, Martin; A. Kushner, Jake; Oron, Tal; G. Parkin, Christopher; R. Pieber, Thomas; W. Rodbard, Helena; Schatz, Desmond; S. Skyler, Jay; V. Tamborlane, William; Yokote, Koutaro; Phillip, Moshe

doi:10.2337/dc18-2316

Public

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Published in Diabetes Care • Feb 6, 2019

Authors:

Thomas Danne

Satish K. Garg

Anne L. Peters

Abstract

Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent stud...

Subject

Medicine

Diabetic ketoacidosis

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!